Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

2.

Stavudine or zidovudine in three-drug combination therapy for initial treatment of HIV infection in antiretroviral-naïve individuals.

Spaulding A, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2010 Aug 4;(8):CD008651. doi: 10.1002/14651858.CD008651. Review.

PMID:
20687097
3.

Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.

van Griensven J, Zachariah R, Rasschaert F, Mugabo J, Atté EF, Reid T.

Trans R Soc Trop Med Hyg. 2010 Feb;104(2):148-53. doi: 10.1016/j.trstmh.2009.07.009. Epub 2009 Sep 3.

PMID:
19732926
4.

Risk factors for and clinical characteristics of severe hyperlactataemia in patients receiving antiretroviral therapy: a case-control study.

Osler M, Stead D, Rebe K, Meintjes G, Boulle A.

HIV Med. 2010 Feb;11(2):121-9. doi: 10.1111/j.1468-1293.2009.00754.x. Epub 2009 Aug 20.

5.

Validation of a portable hand-held lactate analyzer for determination of blood lactate in patients on antiretroviral therapy in Uganda.

Kiragga AK, Ocama P, Reynolds SJ, Kambugu A, Ojiambo H, Castelnuovo B.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):564-6. doi: 10.1097/QAI.0b013e31817e6391. No abstract available.

PMID:
19202460
6.

Symptomatic hyperlactataemia in adults on antiretroviral therapy: a single-centre experience.

Fabian J, Venter WD, Mkhabela L, Levin JB, Baker L, Naicker S.

S Afr Med J. 2008 Oct;98(10):795-800.

PMID:
19115757
7.

Severe hyperlactataemia complicating stavudine first-line antiretroviral therapy in South Africa.

Stead D, Osler M, Boulle A, Rebe K, Meintjes G.

Antivir Ther. 2008;13(7):937-43.

PMID:
19043928
8.

Gender-based differences in treatment and outcome among HIV patients in South India.

Kumarasamy N, Venkatesh KK, Cecelia AJ, Devaleenol B, Saghayam S, Yepthomi T, Balakrishnan P, Flanigan T, Solomon S, Mayer KH.

J Womens Health (Larchmt). 2008 Nov;17(9):1471-5. doi: 10.1089/jwh.2007.0670.

9.

Cost and cost-effectiveness of switching from stavudine to tenofovir in first-line antiretroviral regimens in South Africa.

Rosen S, Long L, Fox M, Sanne I.

J Acquir Immune Defic Syndr. 2008 Jul 1;48(3):334-44. doi: 10.1097/QAI.0b013e31817ae5ef.

PMID:
18545151
10.

Antiretroviral therapy-associated toxicities in the resource-poor world: the challenge of a limited formulary.

Murphy RA, Sunpath H, Kuritzkes DR, Venter F, Gandhi RT.

J Infect Dis. 2007 Dec 1;196 Suppl 3:S449-56. doi: 10.1086/521112. Review.

PMID:
18181693
11.

Higher-than-expected rates of lactic acidosis among highly active antiretroviral therapy-treated women in Botswana: preliminary results from a large randomized clinical trial.

Wester CW, Okezie OA, Thomas AM, Bussmann H, Moyo S, Muzenda T, Makhema J, van Widenfelt E, Musonda R, Novitsky V, Gaolathe T, Ndwapi N, Essex M, Kuritzkes DR, DeGruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2007 Nov 1;46(3):318-22.

PMID:
18090299
12.

Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy.

Lactic Acidosis International Study Group.

AIDS. 2007 Nov 30;21(18):2455-64. Review.

PMID:
18025882
13.

Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort.

Boulle A, Orrel C, Kaplan R, Van Cutsem G, McNally M, Hilderbrand K, Myer L, Egger M, Coetzee D, Maartens G, Wood R; International Epidemiological Databases to Evaluate Aids in Southern Africa Collaboration.

Antivir Ther. 2007;12(5):753-60.

PMID:
17713158
14.
15.

Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment.

Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, Soriano V, Milinkovic A, Gatell J, Ribera E.

Expert Opin Pharmacother. 2007 Apr;8(5):679-88. Review.

PMID:
17376022
16.
17.

Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy.

Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C.

Clin Infect Dis. 2006 Sep 1;43(5):645-53. Epub 2006 Jul 27. Review.

PMID:
16886161
18.

Understanding and avoiding antiretroviral adverse events.

Shibuyama S, Gevorkyan A, Yoo U, Tim S, Dzhangiryan K, Scott JD.

Curr Pharm Des. 2006;12(9):1075-90. Review.

PMID:
16515487
19.
20.

Supplemental Content

Support Center